Consensus Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
6.41 ^USD	+4.23%		+4.06%	-54.02%

03/04	Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating	MT
02/04	Sector Update: Health Care Stocks Slide Late Afternoon	MT

Evolution of the average Target Price on Verve Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3f5b14447bca7618097538a3ec0ba.PFzqw3g2RW9XNSPFMvV9tnNN4EDnY_Q80mKFivyPNh0.TC7esy9UHSs-BXCpfJkvhhc5lDiCO6R1gguwu5DsRFRGH4-CIUQTOSRsQA~51928be446b2a1bbdbdcac7696238b7e

Analyst Recommendations on Verve Therapeutics, Inc.

Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating	03/04	MT
Rate Outlooks Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday	29/11	MT
Guggenheim Adjusts Price Target on Verve Therapeutics to $55 From $56, Maintains Buy Rating	15/23/15	MT
Canaccord Genuity Starts Verve Therapeutics at Buy With $29 Price Target	13/23/13	MT
Credit Suisse Lowers Verve Therapeutics' Price Target to $32 From $37, Maintains Neutral Rating	03/23/03	MT
Cantor Fitzgerald Initiates Verve Therapeutics at Neutral With $21 Price Target	01/23/01	MT
Goldman Sachs Initiates Verve Therapeutics at Sell With $13 Price Target	15/22/15	MT
RBC Cuts Price Target on Verve Therapeutics to $35 From $42, Maintains Outperform, Speculative Risk Rating	08/22/08	MT
Credit Suisse Starts Verve Therapeutics at Neutral with $48 Price Target	06/22/06	MT
Stifel Raises Verve Therapeutics to Buy From Hold, Price Target to $56 From $32	25/22/25	MT
Guggenheim Adjusts Price Target for Verve Therapeutics to $56 From $64, Maintains Buy Rating	26/22/26	MT
BMO Capital Raises Verve Therapeutics' Price Target to $62 From $48, Maintains Outperform Rating, Shares Climb 21%	18/22/18	MT
Verve Therapeutics Shares Rise After BMO Capital Initiates Coverage at Outperform	17/22/17	MT
BMO Capital Initiates Verve Therapeutics at Outperform With $48 Price Target	17/22/17	MT
Guggenheim Cuts Verve Therapeutics Price Target to $64 From $84, Maintains Buy Rating	21/22/21	MT
Stifel Adjusts Verve Therapeutics' Price Target to $34 From $58, Reiterates Hold Rating	15/22/15	MT
RBC Initiates Verve Therapeutics at Outperform-Speculative Risk, Sees 'A Great Entry Point,' Sets Price Target at $42	18/22/18	MT
VERVE THERAPEUTICS : Stifel Starts Verve Therapeutics at Hold With $58 Price Target	24/21/24	MT
VERVE THERAPEUTICS : William Blair Starts Verve Therapeutics at Outperform	12/21/12	MT
VERVE THERAPEUTICS : Guggenheim Initiates Coverage on Verve Therapeutics With Buy Rating, $84 Price Target	12/21/12	MT
VERVE THERAPEUTICS : Jefferies Starts Verve Therapeutics at Buy	12/21/12	MT
VERVE THERAPEUTICS : JPMorgan Starts Verve Therapeutics at Neutral With $50 Price Target	12/21/12	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.41 USD

Average target price

31.22 USD

Spread / Average Target

+387.09%

High Price Target

55 USD

Spread / Highest target

+758.03%

Low Price Target

15 USD

Spread / Lowest Target

+134.01%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Verve Therapeutics, Inc.

Stifel Nicolaus
Guggenheim
Canaccord Genuity
Credit Suisse
Cantor Fitzgerald
Goldman Sachs
RBC Capital Markets
BMO Capital
JPMorgan Chase
Jefferies & Co.
William Blair & Co.

Ratings for Verve Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar